Home
Home

Xtandi

Is This Johnson & Johnson's Worst Nightmare?

Is This Johnson & Johnson's Worst Nightmare?
Motley Fool

New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial Of Enzalutamide In Men With Chemotherapy-Naïve Metastatic Prostate Cancer

New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial Of Enzalutamide In Men With Chemotherapy-Naïve Metastatic Prostate Cancer
Yahoo/BusinessWire

Companies Betting on the Next 10 Blockbuster Drugs

Companies Betting on the Next 10 Blockbuster Drugs
24/7WallStreet

Biotech Stock Roundup: Strong Show from Biogen & Alexion; Medivation PREVAILs

Biotech Stock Roundup: Strong Show from Biogen & Alexion; Medivation PREVAILs
Yahoo/Zacks.com

This Week in Biotech: Let's Get Clinical!

This Week in Biotech: Let's Get Clinical!
Motley Fool

Medivation Inc. and Astellas Up the Ante against Johnson & Johnson

Medivation Inc. and Astellas Up the Ante against Johnson & Johnson
Motley Fool

Medivation prostate cancer drug impresses in pre-chemo study

Medivation prostate cancer drug impresses in pre-chemo study
Yahoo/Reuters

Slowing Sales for Johnson & Johnson's Zytiga May Be Good News for Medivation

Slowing Sales for Johnson & Johnson's Zytiga May Be Good News for Medivation
Motley Fool

Johnson & Johnson And Medivation: A Prostate Cancer Marketshare

Johnson & Johnson And Medivation: A Prostate Cancer Marketshare
Seeking Alpha

Johnson & Johnson Vs. Medivation In Prostate Cancer Race

Johnson & Johnson Vs. Medivation In Prostate Cancer Race
Seeking Alpha